CSIMarket Company Name, Ticker, Competitors, else..
 
Spero Therapeutics Inc   (NASDAQ: SPRO)
Other Ticker:  
 
 
Price: $0.7444 $0.04 6.191%
Day's High: $0.829 Week Perf: 26.19 %
Day's Low: $ 0.72 30 Day Perf: -3.44 %
Volume (M): 368 52 Wk High: $ 1.72
Volume (M$): $ 274 52 Wk Avg: $1.17
Open: $0.72 52 Wk Low: $0.10



 Market Capitalization (Millions $) 40
 Shares Outstanding (Millions) 54
 Employees 75
 Revenues (TTM) (Millions $) 48
 Net Income (TTM) (Millions $) -69
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 0

Spero Therapeutics Inc
Spero Therapeutics Inc is a biopharmaceutical company focused on developing novel therapies to treat multi-drug resistant bacterial infections. The company utilizes its expertise in antimicrobial resistance and drug discovery to develop innovative antibiotics and combination therapies. Spero Therapeutics aims to address the urgent need for new treatments against drug-resistant bacteria, which pose a significant threat to global health. They are committed to developing safe and effective drugs that can combat these infectious diseases and improve patient outcomes.


   Company Address: 675 Massachusetts Avenue, Cambridge 2139 MA
   Company Phone Number: 242-1600   Stock Exchange / Ticker: NASDAQ SPRO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.92%    
JNJ        3.78% 
LLY        14.68% 
MRK   -1.49%    
SNY   -1.19%    
TEVA        3.82% 
• View Complete Report
   



Clinical Study

Spero Therapeutics Phase 1 Data on SPR720 Published Promising Results for Combatting Multidrug-Resistant Tuberculo...

Published Wed, Oct 2 2024 8:30 PM UTC

Spero Therapeutics Announces Significant Progress in Antibacterial Treatment with SPR720: Phase 1 Data Published in Antimicrobial Agents and ChemotherapySpero Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel treatments for bacterial infections, has made significant strides in its quest for effective therapies against multidrug-resistant p...
Shares

Spero Therapeutics Paves the Way for Innovation with Inducement Grant under Nasdaq Listing Rule

Published Wed, Jul 3 2024 5:05 PM UTC

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
In a recent press release, Spero Therapeutics, Inc. (Nasdaq: SPRO) announced that the Compensation Committee of the company s Board of Directors approved the grant of 227,500 restricted stock unit awards (RSUs) to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Ince...
Financing Agreement

Spero Therapeutics Announces Inducement Grant and Improved Financial Performance

Published Mon, Jun 3 2024 8:05 PM UTC


Spero Therapeutics, Inc. recently announced the approval of 116,667 restricted stock unit awards to a new employee as an inducement under the 2019 Inducement Equity Incentive Plan. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) and reflects the company s focus on identifying and developing novel treatments for rare diseases and multi-drug resistan...
Financing Agreement

Spero Therapeutics Empowers New Employee with Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published Wed, May 1 2024 8:08 PM UTC

CAMBRIDGE, Mass., May 01, 2024 - Spero Therapeutics, Inc. (Nasdaq: SPRO), a pioneering biopharmaceutical company specializing in the development of groundbreaking treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, revealed today that it has undertaken a momentous step in its journey. On April 29, 2024, the Compensation Committee of Spero s Boar...
Clinical Study

Clearing a Path for Hope: Spero Therapeutics Advances Novel Polymyxin Antibiotic to Combat Multi-Drug Resistant Gram-Negative Bacterial Infections

Published Wed, Feb 28 2024 1:05 PM UTC

In a significant development, Spero Therapeutics, a renowned clinical-stage biopharmaceutical company, has announced that its investigational new drug (IND) application for SPR206 has received clearance from the U.S. Food and Drug Administration (FDA). This achievement has opened the doors for a Phase 2 clinical study to evaluate the efficacy of SPR206, a next-generation pol...






Spero Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com